Results 201 to 210 of about 30,003 (287)

Biosimilars – Global issues, national solutions

, 2011
Ivana Knežević, Elwyn Griffiths
openalex   +1 more source

India's biosimilar regulations [PDF]

, 2012
Killugudi Jayaraman
openalex   +1 more source

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings. [PDF]

BioDrugs
Kvien TK, Betteridge N, Brückmann I, Bodenmüller W, Bryn G, Danese S, Gonçalves J, Maravic Z, Thorne C, Wingate L, Cornes P.   +10 more
europepmc   +1 more source

Biosimilars and non-innovator biotherapeutics in India: An overview of the current situation

, 2011
Hemant Malhotra
openalex   +1 more source

Austria increases dialogue in order to involve physicians more with biosimilars [PDF]

, 2012
Christoph Baumgärtel
openalex   +1 more source

Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies. [PDF]

Pharmaceuticals (Basel)
Niazi SK.
europepmc   +1 more source

Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System. [PDF]

Children (Basel)
Maltz RM, Saeed SA, Adler J.
europepmc   +1 more source

Associate Editor’s Commentary: The Tao of Biosimilars [PDF]

, 2012
Peter J. Pitts
openalex   +1 more source

Biogeneric versus Biosimilar Products [PDF]

, 2012
Danial E. Baker
openalex   +1 more source

Real-world familiarity with US biosimilar regulatory guidelines and interchangeability state laws among pharmacists and physicians treating immunological disorders. [PDF]

J Manag Care Spec Pharm
Ling YL, Gentile D, Kotomale A, Sharpe JA, Geli D, Gruben D, Omary C, Brackin C, Bailey M.   +8 more
europepmc   +1 more source